查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1572064

青蒿素联合治疗市场：按类型、应用、分销管道、患者年龄层、剂型、治疗类型 - 2025-2030 年全球预测

Artemisinin Combination Therapy Market by Type, Application, Distribution Channel, Patient Age Group, Formulation, Therapy Type - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

青蒿素联合治疗市场2023年估值为3.4118亿美元，预计2024年将达到3.6234亿美元，复合年增长率为6.46%，预计到2030年将达到5.2904亿美元。

青蒿素联合治疗(ACT) 是一种抗疟疗法，使用青蒿素衍生物与伙伴药物联合使用，以提高疗效并抑制抗药性的发展。对 ACT 的需求在于其在快速减少感染疟疾原虫的患者体内的寄生虫载量方面的卓越功效，以及它们在全球抗击疟疾努力中的重要作用。最终用途范围主要是疟疾流行地区的医疗机构，包括医院、诊所和社区健康计画。推动市场成长的主要因素包括全球疟疾负担的增加、国际卫生组织资金的增加以及政府加强疟疾控制计画的努力。由于意识的提高和供应链物流的改善促进了农村地区的准入，需求也在增加。然而，市场面临重大挑战，包括青蒿素部分抗药性的出现、联合治疗的高成本以及获得核准的监管障碍。有机会开发新的药物配方，并扩大 ACT 与先进诊断工具的使用，以进行有针对性的疟疾管理。为了抓住这些机会，公司应专注于旨在克服抗药性和降低成本的研究和创新，包括开发合成衍生物和新型药物输送平台。此外，与公共卫生倡议建立伙伴关係可以在传播和采用方面提供显着优势。市场动态复杂，并受到当地疾病发生率、资金筹措水准和法规环境的影响，需要灵活的商务策略来适应不断变化的条件。在耐受性和成本效益的限制下进行创新至关重要，因此对生物强化学名药和新兴数位健康平台的综合解决方案的研究可能会带来重大进展。总体而言，ACT 市场充满活力但充满挑战，需要策略洞察力和创新方法来实现持续成长和影响。

主要市场统计
基准年[2023] 34118万美元
预测年份 [2024] 3.6234亿美元
预测年份 [2030] 52904万美元
复合年增长率（%） 6.46%

市场动态：快速发展的青蒿素联合治疗市场的关键市场洞察

供需的动态交互作用正在改变青蒿素联合治疗市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 由于疟疾的传播，对青蒿素联合治疗的需求增加
    • 政府推动青蒿素联合疗法使用的倡议
    • 提高人们对联合治疗在疟疾治疗中益处的认识
  • 市场限制因素
    • 製造成本高、供应链效率低
  • 市场机会
    • 活性化政府和私部门对抗疟疾药研究的投资
    • 加强製药公司和研究机构之间的合作和伙伴关係
  • 市场挑战
    • 青蒿素联合治疗全球分销的监管障碍

波特五力策略工具引领青蒿素联合治疗青蒿素

波特的五力架构是了解青蒿素联合治疗市场竞争格局的关键工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解青蒿素联合治疗市场的外部影响

外部宏观环境因素在塑造青蒿素联合治疗市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解青蒿素联合治疗市场的竞争格局

对青蒿素联合治疗市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵青蒿素联合治疗市场供应商绩效评估

FPNV定位矩阵是评估青蒿素联合治疗市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议绘製青蒿素联合治疗市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对青蒿素联合治疗市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 疟疾流行增加了对青蒿素联合治疗的需求
      • 政府推动青蒿素联合治疗使用的倡议
      • 提高人们对联合治疗在疟疾治疗中益处的认识
    • 抑制因素
      • 生产成本高、供应链效率低下
    • 机会
      • 加强政府和私部门对抗疟疾药研究的投资
      • 加强製药公司和研究机构之间的合作和伙伴关係
    • 任务
      • 青蒿素联合治疗全球分销的监管障碍
  • 市场区隔分析
  • 波特五力分析
  • PESTLE分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章青蒿素联合治疗市场：依类型

  • 蒿甲醚-本芴醇
  • 青蒿琥酯阿莫地喹
  • 青蒿琥酯甲氟喹
  • 青蒿酯离胺酸啶
  • 青蒿素-哌喹

第七章青蒿素联合治疗市场：依应用分类

  • 诊所
  • 医院
  • 家庭使用
  • 调查机构

第八章青蒿素联合治疗市场：按分销管道

  • 药局
  • 医院药房
  • 网路药房
  • 零售药房

第 9 章依患者年龄层分類的青蒿素联合治疗市场

  • 成人用
  • 老年病
  • 小儿科

第十章 处方青蒿素联合治疗市场

  • 胶囊
  • 注射
  • 暂停
  • 锭剂

第十一章依治疗类型分類的青蒿素联合治疗市场

  • 联合治疗
  • 一线治疗
  • 单一疗法
  • 二线治疗

第十二章 美洲青蒿素联合治疗青蒿素

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十三章亚太地区青蒿素联合治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十四章欧洲、中东和非洲青蒿素联合治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十五章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议
Product Code: MRR-535C6291884E

The Artemisinin Combination Therapy Market was valued at USD 341.18 million in 2023, expected to reach USD 362.34 million in 2024, and is projected to grow at a CAGR of 6.46%, to USD 529.04 million by 2030.

Artemisinin Combination Therapy (ACT) is an antimalarial treatment that combines an artemisinin derivative with a partner drug to enhance efficacy and reduce resistance development. The necessity of ACT arises from its superior efficacy in rapidly reducing the parasite biomass in patients infected with Plasmodium falciparum and its critical role in global efforts to combat malaria. The application and end-use scope primarily extend to healthcare settings in malaria-endemic regions, involving hospitals, clinics, and community health programs. Key factors driving market growth include the global malaria burden, increased funding from international health organizations, and government initiatives to enhance malaria control programs. There's also rising demand due to increased awareness and improved supply chain logistics facilitating rural access. However, the market faces significant challenges such as the emergence of partial artemisinin resistance, the high cost of combination therapies, and regulatory hurdles in obtaining approvals. Opportunities exist in the development of newer drug formulations and the expansion of ACT use in combination with advanced diagnostic tools for precise malaria management. To seize these opportunities, companies should focus on research and innovation aimed at overcoming resistance and decreasing costs, such as developing synthetic derivatives or novel drug delivery platforms. Encouraging partnerships with public health initiatives can also provide a substantial advantage in dissemination and adoption. The market dynamics are complex, influenced by geographical disease incidence, funding levels, and regulatory environments, which necessitate agile business strategies to adapt to changing landscapes. Innovating within the constraints of resistance and cost-effectiveness will be crucial; therefore, research on bio-enhanced generics or integrative solutions with emerging digital health platforms could usher in significant advancements. Overall, the ACT market is vibrant yet challenging, requiring strategic insights and innovative approaches for sustained growth and impact.

KEY MARKET STATISTICS
Base Year [2023] USD 341.18 million
Estimated Year [2024] USD 362.34 million
Forecast Year [2030] USD 529.04 million
CAGR (%) 6.46%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Artemisinin Combination Therapy Market

The Artemisinin Combination Therapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of malaria leading to increased demand for artemisinin combination therapy
    • Government initiatives promoting the use of artemisinin combination treatments
    • Rising awareness about the advantages of combination therapy for malaria treatment
  • Market Restraints
    • High production costs and supply chain inefficiencies
  • Market Opportunities
    • Heightened government and private sector investments in antimalarial drug research
    • Rising collaborations and partnerships between pharmaceutical companies and research institutes
  • Market Challenges
    • Regulatory hurdles related to the global distribution of artemisinin combination therapy

Porter's Five Forces: A Strategic Tool for Navigating the Artemisinin Combination Therapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Artemisinin Combination Therapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Artemisinin Combination Therapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Artemisinin Combination Therapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Artemisinin Combination Therapy Market

A detailed market share analysis in the Artemisinin Combination Therapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Artemisinin Combination Therapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Artemisinin Combination Therapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Artemisinin Combination Therapy Market

A strategic analysis of the Artemisinin Combination Therapy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Artemisinin Combination Therapy Market, highlighting leading vendors and their innovative profiles. These include Ajanta Pharma Limited, Aurobindo Pharma Limited, Cipla Limited, Dafra Pharma International NV, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Guilin Pharmaceutical Co., Ltd., Ipca Laboratories Limited, KPC Pharmaceuticals, Inc., Merck & Co., Inc., Mylan N.V., Novartis International AG, Pfizer Inc., Ranbaxy Laboratories Limited, Sanofi S.A., Shin Poong Pharmaceutical Co., Ltd., Strides Pharma Science Limited, Sumaya Biotech Pvt. Ltd., Turing Pharmaceuticals AG, and Zydus Cadila.

Market Segmentation & Coverage

This research report categorizes the Artemisinin Combination Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Artemether-Lumefantrine, Artesunate-Amodiaquine, Artesunate-Mefloquine, Artesunate-Pyronaridine, and Dihydroartemisinin-Piperaquine.
  • Based on Application, market is studied across Clinic, Hospital, Household, and Research Institute.
  • Based on Distribution Channel, market is studied across Drug Stores, Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Patient Age Group, market is studied across Adult, Geriatric, and Pediatric.
  • Based on Formulation, market is studied across Capsule, Injection, Suspension, and Tablet.
  • Based on Therapy Type, market is studied across Combination Therapy, First-Line Therapy, Mono Therapy, and Second-Line Therapy.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of malaria leading to increased demand for artemisinin combination therapy
      • 5.1.1.2. Government initiatives promoting the use of artemisinin combination treatments
      • 5.1.1.3. Rising awareness about the advantages of combination therapy for malaria treatment
    • 5.1.2. Restraints
      • 5.1.2.1. High production costs and supply chain inefficiencies
    • 5.1.3. Opportunities
      • 5.1.3.1. Heightened government and private sector investments in antimalarial drug research
      • 5.1.3.2. Rising collaborations and partnerships between pharmaceutical companies and research institutes
    • 5.1.4. Challenges
      • 5.1.4.1. Regulatory hurdles related to the global distribution of artemisinin combination therapy
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Artemisinin Combination Therapy Market, by Type

  • 6.1. Introduction
  • 6.2. Artemether-Lumefantrine
  • 6.3. Artesunate-Amodiaquine
  • 6.4. Artesunate-Mefloquine
  • 6.5. Artesunate-Pyronaridine
  • 6.6. Dihydroartemisinin-Piperaquine

7. Artemisinin Combination Therapy Market, by Application

  • 7.1. Introduction
  • 7.2. Clinic
  • 7.3. Hospital
  • 7.4. Household
  • 7.5. Research Institute

8. Artemisinin Combination Therapy Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Drug Stores
  • 8.3. Hospital Pharmacies
  • 8.4. Online Pharmacies
  • 8.5. Retail Pharmacies

9. Artemisinin Combination Therapy Market, by Patient Age Group

  • 9.1. Introduction
  • 9.2. Adult
  • 9.3. Geriatric
  • 9.4. Pediatric

10. Artemisinin Combination Therapy Market, by Formulation

  • 10.1. Introduction
  • 10.2. Capsule
  • 10.3. Injection
  • 10.4. Suspension
  • 10.5. Tablet

11. Artemisinin Combination Therapy Market, by Therapy Type

  • 11.1. Introduction
  • 11.2. Combination Therapy
  • 11.3. First-Line Therapy
  • 11.4. Mono Therapy
  • 11.5. Second-Line Therapy

12. Americas Artemisinin Combination Therapy Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Artemisinin Combination Therapy Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Artemisinin Combination Therapy Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2023
  • 15.2. FPNV Positioning Matrix, 2023
  • 15.3. Competitive Scenario Analysis
  • 15.4. Strategy Analysis & Recommendation

LIST OF FIGURES

  • FIGURE 1. ARTEMISININ COMBINATION THERAPY MARKET RESEARCH PROCESS
  • FIGURE 2. ARTEMISININ COMBINATION THERAPY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 21. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. ARTEMISININ COMBINATION THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 27. ARTEMISININ COMBINATION THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ARTEMISININ COMBINATION THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ARTEMISININ COMBINATION THERAPY MARKET DYNAMICS
  • TABLE 7. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ARTEMETHER-LUMEFANTRINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ARTESUNATE-AMODIAQUINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ARTESUNATE-MEFLOQUINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ARTESUNATE-PYRONARIDINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DIHYDROARTEMISININ-PIPERAQUINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOUSEHOLD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DRUG STORES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CAPSULE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY SUSPENSION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FIRST-LINE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY MONO THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY SECOND-LINE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. CANADA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. CANADA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. CANADA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 60. CANADA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 61. CANADA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. MEXICO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. MEXICO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. MEXICO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. MEXICO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 66. MEXICO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 67. MEXICO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 72. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 73. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 82. AUSTRALIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. AUSTRALIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. AUSTRALIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 86. AUSTRALIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 87. AUSTRALIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. CHINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. CHINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. CHINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. CHINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 92. CHINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 93. CHINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. INDIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. INDIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. INDIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. INDIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 98. INDIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 99. INDIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. INDONESIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. INDONESIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. INDONESIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. INDONESIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 104. INDONESIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 105. INDONESIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. JAPAN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. JAPAN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. JAPAN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. JAPAN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 110. JAPAN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 111. JAPAN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. MALAYSIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. MALAYSIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. MALAYSIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. MALAYSIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 116. MALAYSIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 117. MALAYSIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. PHILIPPINES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. PHILIPPINES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. PHILIPPINES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 122. PHILIPPINES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 123. PHILIPPINES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. SINGAPORE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SINGAPORE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. SINGAPORE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 127. SINGAPORE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 128. SINGAPORE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 129. SINGAPORE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH KOREA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. SOUTH KOREA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. SOUTH KOREA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 134. SOUTH KOREA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 135. SOUTH KOREA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. TAIWAN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. TAIWAN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. TAIWAN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. TAIWAN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 140. TAIWAN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 141. TAIWAN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. THAILAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. THAILAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. THAILAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 145. THAILAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 146. THAILAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 147. THAILAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. VIETNAM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. VIETNAM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 150. VIETNAM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 151. VIETNAM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 152. VIETNAM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 153. VIETNAM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 161. DENMARK ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. DENMARK ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 163. DENMARK ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 164. DENMARK ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 165. DENMARK ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 166. DENMARK ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. EGYPT ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. EGYPT ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 169. EGYPT ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 170. EGYPT ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 171. EGYPT ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 172. EGYPT ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. FINLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. FINLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 175. FINLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 176. FINLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 177. FINLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 178. FINLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. FRANCE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. FRANCE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 181. FRANCE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 182. FRANCE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 183. FRANCE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 184. FRANCE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. GERMANY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. GERMANY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 187. GERMANY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 188. GERMANY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 189. GERMANY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 190. GERMANY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. ISRAEL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. ISRAEL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 193. ISRAEL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 194. ISRAEL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 195. ISRAEL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 196. ISRAEL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. ITALY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. ITALY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 199. ITALY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 200. ITALY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 201. ITALY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 202. ITALY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. NETHERLANDS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 205. NETHERLANDS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 206. NETHERLANDS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 207. NETHERLANDS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 208. NETHERLANDS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. NIGERIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. NIGERIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 211. NIGERIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 212. NIGERIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 213. NIGERIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 214. NIGERIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. NORWAY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. NORWAY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 217. NORWAY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 218. NORWAY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 219. NORWAY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 220. NORWAY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. POLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. POLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 223. POLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 224. POLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 225. POLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 226. POLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. QATAR ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. QATAR ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 229. QATAR ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 230. QATAR ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 231. QATAR ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 232. QATAR ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. RUSSIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. RUSSIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 235. RUSSIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 236. RUSSIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 237. RUSSIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 238. RUSSIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 240. SAUDI ARABIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 241. SAUDI ARABIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 242. SAUDI ARABIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 243. SAUDI ARABIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 244. SAUDI ARABIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 246. SOUTH AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 247. SOUTH AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 248. SOUTH AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 249. SOUTH AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 250. SOUTH AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 251. SPAIN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 252. SPAIN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 253. SPAIN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 254. SPAIN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 255. SPAIN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 256. SPAIN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 257. SWEDEN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 258. SWEDEN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 259. SWEDEN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 260. SWEDEN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 261. SWEDEN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 262. SWEDEN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 264. SWITZERLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 265. SWITZERLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 266. SWITZERLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 267. SWITZERLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 268. SWITZERLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 269. TURKEY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 270. TURKEY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 271. TURKEY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 272. TURKEY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 273. TURKEY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 274. TURKEY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED ARAB EMIRATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED ARAB EMIRATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 279. UNITED ARAB EMIRATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 280. UNITED ARAB EMIRATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 282. UNITED KINGDOM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 283. UNITED KINGDOM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 284. UNITED KINGDOM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 285. UNITED KINGDOM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 286. UNITED KINGDOM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 287. ARTEMISININ COMBINATION THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 288. ARTEMISININ COMBINATION THERAPY MARKET, FPNV POSITIONING MATRIX, 2023